Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
What neoadjuvant regimen would use you for a patient over 70 years old with resectable gastric cancer?
Related Questions
In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
For a patient with T3N1M0 esophageal adenocarcinoma, who suffered esophageal perforation necessitating metallic stent placement, would you favor a neoadjuvant chemoradiation or perioperative chemotherapy approach?
How would you manage a borderline resectable pancreatic cancer s/p induction chemo + chemo-RT who was unable to go to surgery?
What is your second line therapy for PDL1 negative metastatic squamous esophageal cancer who did not receive a checkpoint inhibitor in first line setting?
Would you consider circulating DNA assay in resected node-negative deficient MMR colon cancer off-trial to guide your treatment?
How would you manage a solitary unresectable liver metastasis?
Would you offer additional systemic treatment to a stage II or III resected colon cancer that received 3 months of adjuvant capecitabine/oxaliplatin and now is presenting with a solitary lung metastasis?
Would you recommend additional post-operative chemoradiation for a T2N1 proximal rectal cancer having received adjuvant capecitabine/oxaliplatin?
In patients with resected PDAC treated with adjuvant FOLFIRINOX who recur from 1-3 years post completion of adjuvant therapy, do you consider retreatment with FOLFIRINOX or gemcitabine/nab-paclitaxel in the absence of a clinical trial?
What is your preferred way of administering nivolumab/ipilimumab in GI cancers?
